KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Common Equity (2018 - 2025)

ClearPoint Neuro's Common Equity history spans 13 years, with the latest figure at $15.9 million for Q3 2025.

  • For Q3 2025, Common Equity fell 45.26% year-over-year to $15.9 million; the TTM value through Sep 2025 reached $15.9 million, down 45.26%, while the annual FY2024 figure was $25.4 million, 19.91% up from the prior year.
  • Common Equity for Q3 2025 was $15.9 million at ClearPoint Neuro, down from $19.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $48.8 million in Q4 2021 and bottomed at $15.9 million in Q3 2025.
  • The 5-year median for Common Equity is $32.6 million (2023), against an average of $33.3 million.
  • The largest annual shift saw Common Equity soared 29510.74% in 2021 before it plummeted 45.26% in 2025.
  • A 5-year view of Common Equity shows it stood at $48.8 million in 2021, then dropped by 24.39% to $36.9 million in 2022, then tumbled by 42.6% to $21.2 million in 2023, then grew by 19.91% to $25.4 million in 2024, then tumbled by 37.48% to $15.9 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's Common Equity are $15.9 million (Q3 2025), $19.7 million (Q2 2025), and $20.0 million (Q1 2025).